Developer docs
API playgroundTry for free, no card

Search company profiles

SpaceGen

Full company profile

uuid000mct5

Namestring
SpaceGen
Legal namestring
Xiamen Spacegen Co., Ltd.
Websiteurl
ispacegen.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

SpaceGen (Xiamen Spacegen Co., Ltd. / 厦门飞朔生物技术有限公司), founded in 2015 and headquartered in Xiamen, China, is a privately held molecular diagnostics company focused on individualized precision testing for solid tumors. The company's stack rests on four core technology platforms: next-generation sequencing (NGS), digital PCR (ddPCR), fluorescence quantitative PCR (PAP-ARMS®), and nucleic acid mass spectrometry (via the Agena MassARRAY system). Proprietary wet-lab methods include RingCap® (a multiplex PCR-based targeted sequencing library prep) and PAP-ARMS® (a high-specificity mutation detection PCR chemistry). SpaceGen has commercialized more than 60 IVD reagent kits spanning companion diagnostics (EGFR, KRAS, BRAF, HER2, ALK, ROS1), tumor multi-gene panels (13-gene and ~1,200-gene panoramas), endometrial cancer molecular subtyping, BRCA1/2 and HRD panels, hematological and rare-cancer assays, and methylation / fusion detection kits (NTRK, RET, MGMT, PAX1). The portfolio carries three NMPA Class III registrations, ten Class I filings, and 25 CE-IVD certifications, with a US patent (US 12,553,152 B2) granted for endometrial-cancer NGS library construction.

Short descriptiontext

SpaceGen is a China-based molecular diagnostics company that develops IVD kits and clinical testing services for precision tumor diagnosis across NGS, digital PCR, fluorescence PCR, and mass spectrometry platforms, serving 5,000+ medical institutions domestically and 100+ institutions across 30+ countries.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersXiamen, China
HQ citystring
Xiamen
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostic products, tumor genetic testing, in vitro diagnostics, precision oncology diagnostics, clinical genetic testing
Industry7 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1IVD Diagnostic Reagent Sales
TypeOne Time License
Description

SpaceGen develops and manufactures over 60 IVD diagnostic reagent products, including next-generation sequencing kits, real-time PCR kits, digital PCR kits, and nucleic acid mass spectrometry kits. These products are sold to hospitals, medical institutions, and laboratories domestically and internationally. 3 products hold NMPA Class III medical device registration certificates, 10 products have Class I medical device filings, and 25 products have CE-IVD certification.

ispacegen.com
2Clinical Laboratory Testing Services
TypeProfessional Services
Description

SpaceGen operates two CLIA-certified clinical laboratories (Xiamen SpaceGen MedLab Co., Ltd. and Suzhou SpaceSeq MedLab Co., Ltd.) providing genetic testing services to hospitals, physicians, and patients. Services cover tumor gene detection, molecular residual disease (MRD) monitoring, and other molecular diagnostic tests.

ispacegen.com
3Equipment and Instruments Sales
TypeHardware Sales
Description

Sale of laboratory equipment and instruments alongside diagnostic reagent kits to support molecular diagnostic testing workflows in clinical settings.

ispacegen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SpaceGen develops, manufactures, and commercializes in vitro diagnostic (IVD) reagent kits for tumor molecular diagnostics and operates clinical testing laboratories providing genetic testing services. Its portfolio covers companion diagnostics (EGFR, KRAS, BRCA, BRAF, ALK, ROS1, NTRK, RET, ESR1, PIK3CA, AKT1, PTEN), MRD monitoring, molecular subtyping (e.g., endometrial ProMisE), and methylation-based screening, built on four core technology platforms: NGS, digital PCR, fluorescence quantitative PCR (PAP-ARMS), and nucleic acid mass spectrometry. Products are sold to hospitals, medical institutions, and overseas distributors, with clinical testing performed at its CAP-accredited MedLab subsidiaries.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SpaceGen offers a comprehensive portfolio of over 60 R&D products and testing services organized around four core technology platforms: Next-Generation Sequencing (NGS), Digital PCR (ddPCR), Fluorescence Quantitative PCR (PAP-ARMS), and Nucleic Acid Mass Spectrometry. The product portfolio spans IVD kits (with 3 NMPA Class III registrations, 10 Class I filings, and 25 CE-IVD certifications) and clinical testing services through two CAP-accredited MedLab subsidiaries (Xiamen SpaceGen MedLab and Suzhou SpaceSeq MedLab). Key product lines include: (1) NGS-based panels — the flagship 6-gene (EGFR/KRAS/BRAF/HER2/ALK/ROS1) semiconductor sequencing kit (RingCap), 13-gene tumor panel, Endometrial Cancer Molecular Subtyping kit, BRCA1/2 panel, HRD Panel Set, and Tumor Panoramic Gene Panel (~1200 genes); (2) PAP-ARMS fluorescence PCR kits — EGFR (29 mutations), KRAS (7 mutations), BRAF, RET fusion, NTRK fusion (32 variants), PAX1 methylation, and MGMT methylation kits; (3) Breast Cancer ESR1 mutation kit (blood-based, 11 mutations); (4) MRD/ctHPV detection services for solid tumors including cervical cancer ctHPV monitoring. The company also provides GMP manufacturing (3500m²) and R&D/quality control laboratories (2000m²).

Product and service2 records
1Human EGFR/KRAS/BRAF/HER2/ALK/ROS1 Gene Mutation Detection Kit (Semiconductor Sequencing, RingCap)
CategoryIVD Kit (NGS)
Description

IVD kit for NSCLC companion diagnostics — simultaneous detection of 6 clinically actionable driver gene mutations (EGFR, KRAS, BRAF, HER2, ALK, ROS1) using semiconductor sequencing with proprietary RingCap chemistry. NMPA Class III registered for clinical use in Chinese hospitals.

2Human Tumor 13 Gene Mutation Detection Kit (NGS)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Zhengzhou Antu Bioengineering Co., Ltd. (郑州安图生物工程股份有限公司)
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-12-01
Description

SpaceGen entered into a strategic cooperation agreement with Antu Bioengineering to build a comprehensive collaboration framework. Antu Bioengineering serves as the primary channel distributor for SpaceGen's sequencing products in China. In March 2026, SpaceGen and Antu Bioengineering jointly hosted a 'Sequencing Products Channel Exchange Conference' in Xiamen with over 100 channel partners from across China. Antu's Sikun gene sequencer series products use 'reversible terminator sequencing' technology and are compatible with SpaceGen's reagents.

ispacegen.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

SpaceGen collaborated with Prof. Zhou Ying's team at the First Affiliated Hospital of USTC on a prospective study (NCT06456112) using ddPCR and NGS to detect circulating tumor HPV DNA (ctHPV) in cervical cancer for MRD monitoring. Results were presented at ASCO 2026. Funded by Anhui Provincial Education Department (2024AH040260).

Strategic tierMajorTypeTechnology or Integration
Description

SpaceGen established a strategic cooperation with Agena Bioscience for nucleic acid mass spectrometry technology. SpaceGen has developed multiple products based on Agena's MassARRAY system, including UGT1A1 gene polymorphism detection and mucormycosis detection kits.

4Guangzhou Darrich Biotech Co., Ltd. (广州市达瑞生物技术股份有限公司)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

SpaceGen signed a strategic cooperation agreement with Darrich Biotech for technology and product collaboration in the molecular diagnostics field. Darrich Biotech also made a Pre-A strategic investment in SpaceGen.

ispacegen.com
5Saisen Biotechnology (Beijing) Co., Ltd. (赛纳生物科技(北京)有限公司)
Strategic tierMajorTypeTechnology or Integration
Description

SpaceGen entered into a strategic cooperation with Saisen Biotechnology and completed a C-round financing of over 100 million RMB. Saisen is a domestic NGS sequencing platform provider, and SpaceGen's products are compatible with the Sikun gene sequencer platform.

ispacegen.com
6Guangzhou Wankadi Molecular Diagnostics Co., Ltd. (广州万孚卡蒂斯生物技术有限公司)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

SpaceGen signed a strategic cooperation agreement with Wankadi Molecular Diagnostics for collaborative development and market expansion in the molecular diagnostics sector.

ispacegen.com
Strategic tierMinorTypeOthers
Description

TUV SÜD certified SpaceGen's quality management system to ISO 13485 standard for medical devices.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Diacarta is a precision diagnostics company developing liquid biopsy and molecular diagnostic tests for cancer detection, including qPCR and NGS-based assays. Comparable to SpaceGen's MRD, ctHPV, and mutation detection products, with overlapping technology approaches (ddPCR, NGS) and oncology focus, but with stronger US clinical presence and FDA submissions.

TypeDirect peer
Description

Burning Rock Biotech is a publicly listed Chinese oncology NGS company providing both central laboratory testing services and IVD reagent kits for cancer companion diagnostics and MRD. It overlaps directly with SpaceGen's tumor precision diagnostics business across multiple cancer types and offers similar evidence-generation at scale through clinical research collaborations.

TypeBroad incumbent
Description

QIAGEN is a global molecular diagnostics and sample technologies leader providing PCR, NGS, and sample preparation solutions for oncology and infectious disease. It overlaps with SpaceGen in the broader molecular diagnostics space (sample prep, PCR reagents, NGS panels) but as a global incumbent with broader portfolio and regulatory reach.

TypeDirect peer
Description

Novogene is a leading Chinese sequencing services provider offering NGS-based oncology testing, genomic profiling, and bioinformatics services to hospitals and research institutions. It is comparable to SpaceGen's clinical laboratory services business (Xiamen SpaceGen MedLab and Suzhou SpaceSeq MedLab) and overlaps in tumor gene sequencing offerings.

TypeEmerging player
Description

Caris Life Sciences is a US-based precision oncology company offering comprehensive molecular profiling (MI Profile), liquid biopsy, and AI-driven analytics. It is comparable to SpaceGen's pan-cancer Tumor Panoramic Gene Panel and HRD Panel in providing comprehensive tumor genomic profiling services, though focused on the US market with different regulatory and reimbursement dynamics.

TypeDirect peer
Description

Amoy Diagnostics (AmoyDx) is a Chinese oncology molecular diagnostics company specializing in PCR and NGS companion diagnostic kits for EGFR, KRAS, BRAF, ALK, ROS1 and other biomarkers. It is the closest direct competitor to SpaceGen in the China NSCLC and colorectal cancer CDx market, with comparable NMPA Class III registrations and CE-IVD certifications.

TypeBroad incumbent
Description

KingMed Diagnostics is China's largest independent third-party medical testing laboratory network. Comparable to SpaceGen's MedLab subsidiaries in providing clinical molecular diagnostic testing services, with significantly broader geographic coverage and test menu depth, but a less oncology-focused product strategy.

8Genetron Health
TypeDirect peer
Description

Genetron Health is a Chinese precision oncology company providing NGS-based cancer profiling, MRD monitoring, and companion diagnostics via both LDT services and IVD products. It competes directly with SpaceGen in the hospital-channel oncology NGS market in China and serves overlapping customer segments of tertiary hospitals and research institutions.

TypeBroad incumbent
Description

BGI Genomics is China's largest genomics company with broad operations across reproductive health, oncology, infectious disease, and agricultural genomics. While not exclusively focused on oncology, BGI competes broadly with SpaceGen in molecular diagnostics, sequencing services, and reagent manufacturing, and operates its own sequencing platform (MGISEQ) compatible with some SpaceGen products.

TypeDirect peer
Description

Agena Bioscience is the US-based developer of the MassARRAY nucleic acid mass spectrometry platform, which SpaceGen integrates with for products like UGT1A1 polymorphism and mucormycosis detection kits. As a strategic technology partner, Agena is comparable in the nucleic acid mass spectrometry segment and represents both an upstream technology provider and a downstream competitive force in this niche modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpaceGen

Molecular Diagnosticsispacegen.com

SpaceGen is a China-based molecular diagnostics company that develops IVD kits and clinical testing services for precision tumor diagnosis across NGS, digital PCR, fluorescence PCR, and mass spectrometry platforms, serving 5,000+ medical institutions domestically and 100+ institutions across 30+ countries.

What SpaceGen does

SpaceGen (Xiamen Spacegen Co., Ltd. / 厦门飞朔生物技术有限公司), founded in 2015 and headquartered in Xiamen, China, is a privately held molecular diagnostics company focused on individualized precision testing for solid tumors. The company's stack rests on four core technology platforms: next-generation sequencing (NGS), digital PCR (ddPCR), fluorescence quantitative PCR (PAP-ARMS®), and nucleic acid mass spectrometry (via the Agena MassARRAY system). Proprietary wet-lab methods include RingCap® (a multiplex PCR-based targeted sequencing library prep) and PAP-ARMS® (a high-specificity mutation detection PCR chemistry). SpaceGen has commercialized more than 60 IVD reagent kits spanning companion diagnostics (EGFR, KRAS, BRAF, HER2, ALK, ROS1), tumor multi-gene panels (13-gene and ~1,200-gene panoramas), endometrial cancer molecular subtyping, BRCA1/2 and HRD panels, hematological and rare-cancer assays, and methylation / fusion detection kits (NTRK, RET, MGMT, PAX1). The portfolio carries three NMPA Class III registrations, ten Class I filings, and 25 CE-IVD certifications, with a US patent (US 12,553,152 B2) granted for endometrial-cancer NGS library construction.

SpaceGen firmographics

Firmographics
Name
SpaceGen
Legal name
Xiamen Spacegen Co., Ltd.
Website
https://ispacegen.com
Company type
Private
Founded year
2015
Headcount range
1–10 employees
Short description
SpaceGen is a China-based molecular diagnostics company that develops IVD kits and clinical testing services for precision tumor diagnosis across NGS, digital PCR, fluorescence PCR, and mass spectrometry platforms, serving 5,000+ medical institutions domestically and 100+ institutions across 30+ countries.
Ownership category
akta.pro rank

SpaceGen industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Molecular diagnostic products
  • Tumor genetic testing
  • In vitro diagnostics
  • Precision oncology diagnostics
  • Clinical genetic testing

Where SpaceGen is headquartered

Location

Headquarters

HQ city
Xiamen
HQ country
China
HQ region
Asia

Offices2 records

Markets served

SpaceGen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. IVD Diagnostic Reagent Sales: SpaceGen develops and manufactures over 60 IVD diagnostic reagent products, including next-generation sequencing kits, real-time PCR kits, digital PCR kits, and nucleic acid mass spectrometry kits. These products are sold to hospitals, medical institutions, and laboratories domestically and internationally. 3 products hold NMPA Class III medical device registration certificates, 10 products have Class I medical device filings, and 25 products have CE-IVD certification.
  2. Clinical Laboratory Testing Services: SpaceGen operates two CLIA-certified clinical laboratories (Xiamen SpaceGen MedLab Co., Ltd. and Suzhou SpaceSeq MedLab Co., Ltd.) providing genetic testing services to hospitals, physicians, and patients. Services cover tumor gene detection, molecular residual disease (MRD) monitoring, and other molecular diagnostic tests.
  3. Equipment and Instruments Sales: Sale of laboratory equipment and instruments alongside diagnostic reagent kits to support molecular diagnostic testing workflows in clinical settings.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

SpaceGen product offering

Product offering

Core offering

SpaceGen develops, manufactures, and commercializes in vitro diagnostic (IVD) reagent kits for tumor molecular diagnostics and operates clinical testing laboratories providing genetic testing services. Its portfolio covers companion diagnostics (EGFR, KRAS, BRCA, BRAF, ALK, ROS1, NTRK, RET, ESR1, PIK3CA, AKT1, PTEN), MRD monitoring, molecular subtyping (e.g., endometrial ProMisE), and methylation-based screening, built on four core technology platforms: NGS, digital PCR, fluorescence quantitative PCR (PAP-ARMS), and nucleic acid mass spectrometry. Products are sold to hospitals, medical institutions, and overseas distributors, with clinical testing performed at its CAP-accredited MedLab subsidiaries.

Product overview

SpaceGen offers a comprehensive portfolio of over 60 R&D products and testing services organized around four core technology platforms: Next-Generation Sequencing (NGS), Digital PCR (ddPCR), Fluorescence Quantitative PCR (PAP-ARMS), and Nucleic Acid Mass Spectrometry. The product portfolio spans IVD kits (with 3 NMPA Class III registrations, 10 Class I filings, and 25 CE-IVD certifications) and clinical testing services through two CAP-accredited MedLab subsidiaries (Xiamen SpaceGen MedLab and Suzhou SpaceSeq MedLab). Key product lines include: (1) NGS-based panels — the flagship 6-gene (EGFR/KRAS/BRAF/HER2/ALK/ROS1) semiconductor sequencing kit (RingCap), 13-gene tumor panel, Endometrial Cancer Molecular Subtyping kit, BRCA1/2 panel, HRD Panel Set, and Tumor Panoramic Gene Panel (~1200 genes); (2) PAP-ARMS fluorescence PCR kits — EGFR (29 mutations), KRAS (7 mutations), BRAF, RET fusion, NTRK fusion (32 variants), PAX1 methylation, and MGMT methylation kits; (3) Breast Cancer ESR1 mutation kit (blood-based, 11 mutations); (4) MRD/ctHPV detection services for solid tumors including cervical cancer ctHPV monitoring. The company also provides GMP manufacturing (3500m²) and R&D/quality control laboratories (2000m²).

Differentiator

Problem solved

Functional benefit

Products and services

  • Human EGFR/KRAS/BRAF/HER2/ALK/ROS1 Gene Mutation Detection Kit (Semiconductor Sequencing, RingCap) IVD kit for NSCLC companion diagnostics — simultaneous detection of 6 clinically actionable driver gene mutations (EGFR, KRAS, BRAF, HER2, ALK, ROS1) using semiconductor sequencing with proprietary RingCap chemistry. NMPA Class III registered for clinical use in Chinese hospitals.
  • Human Tumor 13 Gene Mutation Detection Kit (NGS)

Companies that use SpaceGen

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

SpaceGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

SpaceGen partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major and minor.

  • Zhengzhou Antu Bioengineering Co., Ltd. (郑州安图生物工程股份有限公司)majorChannel Partner/ Reseller/ Distributor · 1 December 2024SpaceGen entered into a strategic cooperation agreement with Antu Bioengineering to build a comprehensive collaboration framework. Antu Bioengineering serves as the primary channel distributor for SpaceGen's sequencing products in China. In March 2026, SpaceGen and Antu Bioengineering jointly hosted a 'Sequencing Products Channel Exchange Conference' in Xiamen with over 100 channel partners from across China. Antu's Sikun gene sequencer series products use 'reversible terminator sequencing' technology and are compatible with SpaceGen's reagents.
  • Chinese Academy of Sciences University of Science and Technology - First Affiliated Hospital (中国科学技术大学附属第一医院/安徽省立医院) - Prof. Zhou Ying TeammajorStrategic or Co-development Partner · 1 January 2024SpaceGen collaborated with Prof. Zhou Ying's team at the First Affiliated Hospital of USTC on a prospective study (NCT06456112) using ddPCR and NGS to detect circulating tumor HPV DNA (ctHPV) in cervical cancer for MRD monitoring. Results were presented at ASCO 2026. Funded by Anhui Provincial Education Department (2024AH040260).
  • Agena Bioscience (美国Agena Bioscience)majorTechnology or IntegrationSpaceGen established a strategic cooperation with Agena Bioscience for nucleic acid mass spectrometry technology. SpaceGen has developed multiple products based on Agena's MassARRAY system, including UGT1A1 gene polymorphism detection and mucormycosis detection kits.
  • Guangzhou Darrich Biotech Co., Ltd. (广州市达瑞生物技术股份有限公司)majorStrategic or Co-development PartnerSpaceGen signed a strategic cooperation agreement with Darrich Biotech for technology and product collaboration in the molecular diagnostics field. Darrich Biotech also made a Pre-A strategic investment in SpaceGen.
  • Saisen Biotechnology (Beijing) Co., Ltd. (赛纳生物科技(北京)有限公司)majorTechnology or IntegrationSpaceGen entered into a strategic cooperation with Saisen Biotechnology and completed a C-round financing of over 100 million RMB. Saisen is a domestic NGS sequencing platform provider, and SpaceGen's products are compatible with the Sikun gene sequencer platform.
  • Guangzhou Wankadi Molecular Diagnostics Co., Ltd. (广州万孚卡蒂斯生物技术有限公司)minorStrategic or Co-development PartnerSpaceGen signed a strategic cooperation agreement with Wankadi Molecular Diagnostics for collaborative development and market expansion in the molecular diagnostics sector.
  • TUV SÜD (南德TUV)minorOthersTUV SÜD certified SpaceGen's quality management system to ISO 13485 standard for medical devices.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

SpaceGen competitors and assessment

Company assessment

Emerging players

  • Diacarta: Diacarta is a precision diagnostics company developing liquid biopsy and molecular diagnostic tests for cancer detection, including qPCR and NGS-based assays. Comparable to SpaceGen's MRD, ctHPV, and mutation detection products, with overlapping technology approaches (ddPCR, NGS) and oncology focus, but with stronger US clinical presence and FDA submissions.
  • Caris Life Sciences: Caris Life Sciences is a US-based precision oncology company offering comprehensive molecular profiling (MI Profile), liquid biopsy, and AI-driven analytics. It is comparable to SpaceGen's pan-cancer Tumor Panoramic Gene Panel and HRD Panel in providing comprehensive tumor genomic profiling services, though focused on the US market with different regulatory and reimbursement dynamics.

Direct peers

  • Burning Rock Biotech: Burning Rock Biotech is a publicly listed Chinese oncology NGS company providing both central laboratory testing services and IVD reagent kits for cancer companion diagnostics and MRD. It overlaps directly with SpaceGen's tumor precision diagnostics business across multiple cancer types and offers similar evidence-generation at scale through clinical research collaborations.
  • Novogene: Novogene is a leading Chinese sequencing services provider offering NGS-based oncology testing, genomic profiling, and bioinformatics services to hospitals and research institutions. It is comparable to SpaceGen's clinical laboratory services business (Xiamen SpaceGen MedLab and Suzhou SpaceSeq MedLab) and overlaps in tumor gene sequencing offerings.
  • Amoy Diagnostics: Amoy Diagnostics (AmoyDx) is a Chinese oncology molecular diagnostics company specializing in PCR and NGS companion diagnostic kits for EGFR, KRAS, BRAF, ALK, ROS1 and other biomarkers. It is the closest direct competitor to SpaceGen in the China NSCLC and colorectal cancer CDx market, with comparable NMPA Class III registrations and CE-IVD certifications.
  • Genetron Health: Genetron Health is a Chinese precision oncology company providing NGS-based cancer profiling, MRD monitoring, and companion diagnostics via both LDT services and IVD products. It competes directly with SpaceGen in the hospital-channel oncology NGS market in China and serves overlapping customer segments of tertiary hospitals and research institutions.
  • Agena Bioscience: Agena Bioscience is the US-based developer of the MassARRAY nucleic acid mass spectrometry platform, which SpaceGen integrates with for products like UGT1A1 polymorphism and mucormycosis detection kits. As a strategic technology partner, Agena is comparable in the nucleic acid mass spectrometry segment and represents both an upstream technology provider and a downstream competitive force in this niche modality.

Broad incumbents

  • QIAGEN: QIAGEN is a global molecular diagnostics and sample technologies leader providing PCR, NGS, and sample preparation solutions for oncology and infectious disease. It overlaps with SpaceGen in the broader molecular diagnostics space (sample prep, PCR reagents, NGS panels) but as a global incumbent with broader portfolio and regulatory reach.
  • KingMed Diagnostics: KingMed Diagnostics is China's largest independent third-party medical testing laboratory network. Comparable to SpaceGen's MedLab subsidiaries in providing clinical molecular diagnostic testing services, with significantly broader geographic coverage and test menu depth, but a less oncology-focused product strategy.
  • BGI Genomics: BGI Genomics is China's largest genomics company with broad operations across reproductive health, oncology, infectious disease, and agricultural genomics. While not exclusively focused on oncology, BGI competes broadly with SpaceGen in molecular diagnostics, sequencing services, and reagent manufacturing, and operates its own sequencing platform (MGISEQ) compatible with some SpaceGen products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SpaceGen compliance and trust

Trust signal

Compliance8 records

SpaceGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpaceGen leadership team

Management profile

Number of profiles

Profiles1 record

SpaceGen subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

SpaceGen funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpaceGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpaceGen

What does SpaceGen do?

SpaceGen develops, manufactures, and commercializes in vitro diagnostic (IVD) reagent kits for tumor molecular diagnostics and operates clinical testing laboratories providing genetic testing services. Its portfolio covers companion diagnostics (EGFR, KRAS, BRCA, BRAF, ALK, ROS1, NTRK, RET, ESR1, PIK3CA, AKT1, PTEN), MRD monitoring, molecular subtyping (e.g., endometrial ProMisE), and methylation-based screening, built on four core technology platforms: NGS, digital PCR, fluorescence quantitative PCR (PAP-ARMS), and nucleic acid mass spectrometry. Products are sold to hospitals, medical institutions, and overseas distributors, with clinical testing performed at its CAP-accredited MedLab subsidiaries.

Is SpaceGen a public or private company?

SpaceGen is a private company. It is classified as venture growth investor backed.

When was SpaceGen founded?

SpaceGen was founded in 2015. It employs 1 to 10 people.

Where is SpaceGen based?

SpaceGen is headquartered in Xiamen, China, in the Asia region.

How does SpaceGen make money?

Three revenue lines are on record. IVD Diagnostic Reagent Sales are the primary driver. The others are clinical Laboratory Testing Services and equipment and Instruments Sales.

Who are SpaceGen's main competitors?

Emerging players on record are Diacarta and Caris Life Sciences. Direct peers are Burning Rock Biotech, Novogene, Amoy Diagnostics, Genetron Health and Agena Bioscience. Broad incumbents are QIAGEN, KingMed Diagnostics and BGI Genomics.

Does SpaceGen have an API?

No public API is recorded for SpaceGen.

What industry is SpaceGen in?

SpaceGen's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales